Technology

Cassava Sciences

$12.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.79 (+6.54%) Today
$0.00 (0.00%) As of 10:24 AM UTC after-hours

Why Robinhood?

You can buy or sell SAVA and other stocks, options, and ETFs commission-free!

About SAVA

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. The listed name for SAVA is Cassava Sciences, Inc. Common Stock.

CEO
Remi Barbier
Employees
9
Headquarters
Austin, Texas
Founded
1998
Market Cap
455.81M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
4.92M
High Today
$13.77
Low Today
$11.71
Open Price
$11.79
Volume
2.99M
52 Week High
$13.78
52 Week Low
$1.63

Collections

SAVA Earnings

-$0.08
-$0.05
-$0.03
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, Pre-Market

You May Also Like

MGC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure